Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
Authors
Keywords
-
Journal
BMC Medicine
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-01
DOI
10.1186/s12916-021-02089-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging therapeutic agents for advanced non-small cell lung cancer
- (2020) Ruqin Chen et al. Journal of Hematology & Oncology
- Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer
- (2020) Siddhartha Devarakonda et al. CANCER CELL
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer
- (2019) Wenfeng Fang et al. CLINICAL CANCER RESEARCH
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- (2019) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
- (2019) Aaron C. Tan et al. LUNG CANCER
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
- (2018) Carolyn J. Presley et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Broad Genomic Testing in NSCLC: No Survival Benefit?
- (2018) Cancer Discovery
- Redefining the Value Proposition of Precision Oncology
- (2018) Howard (Jack) West JAMA Oncology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- Perspective: The precision-oncology illusion
- (2016) Vinay Prasad NATURE
- Limits to Personalized Cancer Medicine
- (2016) Ian F. Tannock et al. NEW ENGLAND JOURNAL OF MEDICINE
- No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing
- (2016) Howard (Jack) West JAMA Oncology
- Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
- (2015) M. Takeda et al. ANNALS OF ONCOLOGY
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
- (2015) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now